PSEN1 and Alzheimer disease: Further characterization of CSF–PS1 complexes has yet to be conducted in order to define the appropriate methodological approach for evaluating their feasibility as a potential new AD biomarker, as well evaluation of its diagnostic performance in comparison with existing biomarkers such as Aβ.